# US 2006/0069029 A1 · Exendin analog formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0069029 A1
- Document ID: US20060069029A1
- Status: Published application
- Kind: A1
- Application number: 11/272,488
- Filed: 2005-11-10
- Published: 2006-03-30
- Earliest claimed: 1999-01-14
- Assignees: Amylin Pharmaceuticals, Inc.
- Inventors: Orville Kolterman; Andrew Young; James L'Italien
- Web page: https://patentgrep.com/patent/US20060069029A1

## CPC

- C07K 14/605: Glucagons
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/26: Glucagons
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- C07K 14/57563: {Vasoactive intestinal peptide [VIP]; Related peptides}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.

## Claims

### Claim 1

A pharmaceutical formulation which is a liquid dosage form suitable for multi-use administration comprising about 0.005% (w/v) to about 0.4% (w/v) of an exendin, an exendin analog or a combination thereof, a buffer, an iso-osmolality modifier, and about 0.005% to about 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, phenol, benzyl alcohol, methyl-, ethyl-, propyl- and butyl-paraben and any combination thereof, wherein said formulation has a pH of between about 3.0 and about 7.0 and said exendin is not exendin-4.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin is exendin-3.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin analog comprises SEQ ID NO. 41.

### Claim 4 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin analog comprises SEQ ID NO. 42.

### Claim 5 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin analog comprises SEQ ID NO. 43.

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin analog comprises SEQ ID NO. 44.

### Claim 7 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin analog comprises SEQ ID NO. 45.

### Claim 8 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin analog comprises SEQ ID NO. 46.

### Claim 9 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin analog comprises SEQ ID NO. 47.

### Claim 10 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin analog comprises SEQ ID NO. 48.

### Claim 11 (depends on 1)

The pharmaceutical formulation of claim 1, where said exendin analog is selected from at least one of the group consisting of SEQ ID NOs 6-189.

### Claim 12 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said exendin analog is selected from at least one of the group consisting of SEQ ID NOs 6, 7, 8, 9, 40 and 41.

### Claim 13 (depends on 1)

The formulation of claim 1, said formulation having a pH of between about 4.0 and about 6.0.

### Claim 14 (depends on 1)

The formulation of claim 1, wherein said pH is between about 4.0 and about 5.0.

### Claim 15 (depends on 1)

The formulation of claim 1, wherein said exendin or exendin analog is present at a concentration of between about 0.005% (w/v) and about 0.05% (w/v).

### Claim 16 (depends on 1)

The formulation of claim 1, wherein said buffer is selected from the group consisting of an acetate buffer, a glutamate buffer, a citrate buffer, a phosphate buffer, and any combination thereof.

### Claim 17 (depends on 1)

The formulation of claim 1, wherein said buffer is at a concentration between about 0.02% (w/v) and about 0.5% (w/v).

### Claim 18 (depends on 1)

The formulation of claim 1, wherein said iso-osmolality modifier is a carbohydrate, a polyhydric alcohol, or a combination thereof, and said iso-osmolality modifier is at a concentration between about 1% (w/v) and 10% (w/v).

### Claim 19 (depends on 18)

The formulation of claim 18, wherein said polyhydric alcohol is selected from the group consisting of sorbitol, mannitol, inositol, glycerol, xylitol, polyethylene glycols, and any combination thereof.

### Claim 20 (depends on 18)

The formulation of claim 18, wherein said carbohydrate is selected from the group consisting of galactose, arabinose, lactose, and any combination thereof.

### Claim 21 (depends on 1)

The formulation of claim 1, wherein said iso-osmolality modifier is mannitol, sorbitol, or a combination thereof.

### Claim 22 (depends on 1)

The formulation of claim 1, wherein said preservative is m-cresol, phenol or a combination thereof.

### Claim 23 (depends on 1)

The formulation of claim 1, wherein said formulation is suitable for administration via injection to achieve a dose of from about 0.1 μg/kg to about 0.5 μg/kg of said exendin or exendin analog.

### Claim 24 (depends on 1)

The formulation of claim 1, wherein said formulation is suitable for administration via injection to achieve a dose of from about 0.005 μg/kg to about 0.2 μg/kg of said exendin or exendin analog.

### Claim 25 (depends on 1)

The formulation of claim 1, wherein said formulation is suitable for administration via injection to achieve a dose of from about 1 μg/day to about 1 mg/day of said exendin or exendin analog.

### Claim 26

A pharmaceutical formulation which is a liquid dosage form suitable for multi-use administration comprising an exendin, an exendin analog or a combination thereof, a buffer, an iso-osmolality modifier, and about 0.005% (w/v) to about 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, phenol, benzyl alcohol, methyl-, ethyl-, propyl- and butyl-paraben and any combination thereof, wherein said formulation has a pH of between about 3.0 and about 6.0 and said exendin is not exendin-4.

### Claim 27 (depends on 26)

The formulation of claim 26, wherein said formulation is suitable for a route of administration selected from the group consisting of:
oral administration to achieve a dose of from about 500 μg/day to about 12,000 μg/day of said exendin or exendin analog in a single or divided dose;
pulmonary administration to achieve a dose from about 100 μg/day to about 12,000 μg/day of said exendin or exendin analog in a single or divided dose;
sublingual administration to achieve a dose from about 10 μg/day to about 8,000 μg/day of said exendin or exendin analog in a single or divided dose;
nasal administration to achieve a dose from about 10 μg/day to about 12,000 μg/day of said exendin or exendin analog in a single or divided dose; and
buccal administration to achieve a dose from about 100 μg/day to about 12,000 μg/day of said exendin or exendin analog in a single or divided dose.

### Claim 28 (depends on 26)

The formulation of claim 26, said formulation having a pH of between about 4.0 and about 6.0.

### Claim 29 (depends on 26)

The formulation of claim 26, wherein said pH is between about 4.0 and about 5.0.

### Claim 30 (depends on 26)

The formulation of claim 26, wherein said buffer is selected from the group consisting of an acetate buffer, a glutamate buffer, a citrate buffer, a phosphate buffer, and any combination thereof.

### Claim 31 (depends on 26)

The formulation of claim 26, wherein said buffer is at a concentration between about 0.02% (w/v) and about 0.5% (w/v).

### Claim 32 (depends on 26)

The formulation of claim 26, wherein said iso-osmolality modifier is a carbohydrate, a polyhydric alcohol, or a combination thereof, and said iso-osmolality modifier is at a concentration between about 1% (w/v) and 10% (w/v).

### Claim 33 (depends on 26)

The formulation of claim 26, wherein said polyhydric alcohol is selected from the group consisting of sorbitol, mannitol, inositol, glycerol, xylitol, polyethylene glycols, and any combination thereof.

### Claim 34 (depends on 26)

The formulation of claim 26, wherein said carbohydrate is selected from the group consisting of galactose, arabinose, lactose, and any combination thereof.

### Claim 35 (depends on 26)

The formulation of claim 26, wherein said iso-osmolality modifier is mannitol, sorbitol, or a combination thereof.

### Claim 36 (depends on 26)

The formulation of claim 26, wherein said preservative is m-cresol, phenol or a combination thereof.
